Environmental and lifestyle factors, such as certain foods and infections, may trigger onset of psoriasis and account for approximately 30% of the risk of the condition in people with a genetic preposition, research presented in London shows.
Switching from adalimumab to etanercept or vice versa after interruption can improve treatment response, data presented in London suggests.
Phase three trials of the selective IL-23 blocker risankizumab are replicating the promising results achieved by phase two trials for psoriasis, researchers report in London.
Secukinumab has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis in hard-to-treat patients who failed anti-TNFa treatment, researchers report in London.
Adding caffeine to topical skin treatments would be a simple way to reduce inflammation in patients with atopic dermatitis and psoriasis, suggests a review presented at the Psoriasis: From Gene to Clinic International Congress, which took place in London this week.
Patients with psoriasis are more likely than the general population to receive a diagnosis of malignant lymphoma. Why? Cutaneous T-cell lymphoma is misdiagnosed as psoriasis and can also be mistaken for atopic dermatitis due to similarities in the skin manifestation.